IMARC Group, a leading market research company, has recently releases report titled “Influenza Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global influenza diagnostics market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How Big Is The Influenza Diagnostics Market?
The global influenza diagnostics market size reached US$ 893.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,461.7 Million by 2028, exhibiting a growth rate (CAGR) of 6.55% during 2023-2028.
What are Influenza Diagnostics?
Influenza or flu is a highly contagious infectious disease caused by a virus. It affects the nose, throat, and lungs and causes severe aches and fever. It is diagnosed through immunofluorescence assays, serology, viral culture, rapid antigen testing, rapid influenza diagnostic tests (RIDTs), reverse transcription polymerase chain reaction (RT-PCR), and rapid molecular assays. These procedures include several immunoassay tests to detect the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and provide the result in a qualitative way as positive or negative. As a result, influenza diagnostic solutions are extensively adopted in hospitals and diagnostic laboratories across the globe.
What Are The Growth Prospects And Trends In The Influenza Diagnostics Industry?
The market is primarily driven by the growing prevalence of chronic diseases that increases the risk of influenza, including cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis. In addition, the increasing popularity of the rapid influenza diagnostic test (RIDT), which is convenient to use and offers results in fewer minutes, is accelerating the product adoption rate across the globe.
Moreover, the introduction of technologically advanced influenza diagnostics tests integrated with a combo of influenza A and B and coronavirus disease (COVID-19) rapid antigen tests represents another major growth-inducing factor. Besides this, the rising integration of artificial intelligence (AI) in influenza diagnostics to reduce timelines for sample processing and facilitate error-free results are providing a positive thrust to the market growth. Furthermore, the rising geriatric population prone to respiratory tract infections and the implementation of various government policies to reduce the risk of influenza are propelling market growth..
What Is Included In Market Segmentation?
The report has segmented the market into the following categories:
Breakup by Product:
- Test Kit and Reagents
- Instruments
- Others
Breakup by Test Type:
- Molecular Diagnostic Tests
- Polymerase Chain Reaction
- Isothermal Nucleic Acid Amplification Tests
- Other Molecular Tests
- Traditional Diagnostic Tests
- Rapid Influenza Diagnostic Tests
- Viral Culture Tests
- Direct Fluorescent Antibody Test
- Serological Tests
Breakup by Type of Flu:
- Type A Flu
- Type B Flu
- Type C Flu
Breakup by End User:
- Hospitals
- Diagnostic Laboratories
- Others
Diagnostic Centres Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who Are The Key Players Operating In The Industry?
The report covers the major market players including:
- Abbott Laboratories
- Becton Dickinson and Company
- Coris Bioconcept
- Danaher Corporation
- DiaSorin S.p.A.
- Hoffmann-La Roche Ltd (Roche Holding AG)
- Hologic Inc.
- Meridian Bioscience Inc.
- Qiagen N.V, Quidel Corporation
- Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
- and Siemens Healthineers AG (Siemens AG)
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/influenza-diagnostics-market
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: [email protected]
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/